Vertex Pharmaceuticals is giving 340B covered entities refunds for overcharges from Q2 2021 through Q4 2021 on its cystic fibrosis combination medicine Trikafta.

Vertex Providing Refunds for 340B Overcharges on Cystic Fibrosis Drug Trikafta

Biopharmaceutical company Vertex is providing refunds to 340B covered entities for overcharges on its cystic fibrosis (CF) combination medicine Trikafta for the period from Q2 2021 through Q4 2021, according to a public notice on the U.S. Health Resources and Services Administration website.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report